

Editorials

- Education in Musculoskeletal Health — How Can It Be Improved to Meet Growing Needs?**
A.D. Woolf, K. Åkesson 455
- Curriculum Design: Finding a Balance**
L.J. Albert 458
- Rheumatoid Arthritis and Diabetes Mellitus: Evidence for an Association?**
M. Doran 460
- Is Minimal Clinically Important Difference Relevant for the Interpretation of Clinical Trials in Pediatric Rheumatic Diseases?**
N. Ruperto 463
- Role of Thrombotic and Fibrinolytic Alterations in the Pathogenesis and Treatment of Osteonecrosis**
M.A. Mont, S.D. Ulrich, T.M. Seyler 466

Articles

- Prevalent RA and Diabetes Among NHANES III Participants Aged 60 and Older**
J.F. Simard, M.A. Mittleman 469
- Infliximab Does Not Suppress the Tuberculin Skin Test (PPD)** *G. Hatemi, M. Melikoglu, I. Fresko, S. Masatlioglu, K. Tascilar, H. Yazici* 474
- Work Disability in RA — Development Over 15 Years and Evaluation of Predictive Factors Over Time**
K. Eberhardt, B-M. Larsson, K. Nived, E. Lindqvist . . 481
- Hypothesis Adipose Tissue as a Modulator of Clinical Inflammation: Does Obesity Reduce the Prevalence of RA?**
T. Bartfai, J. Waalen, J.N. Buxbaum 488
- Toll-like Receptor Expression in Lupus PBMC**
K. Migita, T. Miyashita, Y. Maeda, et al 493
- Outcome Measurements in Scleroderma: Results from a Delphi Exercise**
H. Gazi, J.E. Pope, P. Clements, et al 501
- Safety and Efficacy of Readministration of Infliximab After Longterm Continuous Therapy and Withdrawal in Patients with AS**
X. Baraliakos, J. Listing, M. Rudwaleit, et al 510

Low Molecular Weight Phenotype of Apo(a) Is a Risk Factor of Corticosteroid-Induced Osteonecrosis of the Femoral Head After Renal Transplant

T. Hirata, M. Fujioka, K.A. Takahashi, et al 516

Adenoviral Gene Transfer of the Endogenous Inhibitor I κ B α into Human OA Synovial Fibroblasts Demonstrates That Several MMP and Aggrecanases Are NF- κ B-Dependent

J. Bondeson, S. Lauder, S. Wainwright, et al 523

A Model to Estimate HUI3 Utility Scores from WOMAC Index Scores in Patients with OA of the Knee

P. Grootendorst, D. Marshall, D. Pericak, N. Bellamy, D. Feeny, G.W. Torrance 534

Tramadol for OA: A Systematic Review and Metaanalysis

M.S. Cepeda, F. Camargo, C. Zea, L. Valencia 543

Cyclic Compression Loaded on Cartilage Explants Enhances the Production of ROS

T. Tomiyama, K. Fukuda, K. Yamazaki, et al 556

Evaluation of the Activity of an Academic Rheumatology Consult Service Over 10 Years: Using Data to Shape Curriculum

K. Ta, G.C. Gardner 563

Canadian Multidisciplinary Core Curriculum for Musculoskeletal Health

V.M.R. Wadey, E. Tang, G. Abelseth, P. Dev, R.A. Olshen, D. Walker 567

Pediatric Rheumatology

The Quality of My Life Questionnaire: The Minimal Clinically Important Difference for Pediatric Rheumatology Patients

G.W.K. Gong, N.L. Young, H. Dempster, M. Porepa, B.M. Feldman 581

Case Report

Mycophenolate Mofetil and IV Dexamethasone in the Treatment of Persistent Lupus Myelitis

P. Tomietto, S. D'Agostini, V. Annese, S. De Vita, G. Ferraccioli 588

Rapid Acetabular Osteolysis Secondary to Subchondral Insufficiency Fracture

T. Yamamoto, R. Schneider, Y. Iwamoto, P.G. Bullough 592

Contents continued opposite inside back cover . . .

Images in Rheumatology

Joint Destruction in Septic Arthritis *I. Uthman* . . . 596

OMERACT 8

International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, St. Julian's Bay, Malta, May 10-14, 2006

Introduction *M. Boers, V. Strand, L.S. Simon, P. Tugwell, P. Brooks* 599

Biomarkers and Surrogate Endpoints

The WHO International Classification of Functioning, Disability and Health: A Conceptual Model and Interface for the OMERACT Process *G. Stucki, A. Boonen, P. Tugwell, A. Cieza, M. Boers* 600

Definitions and Validation Criteria for Biomarkers and Surrogate Endpoints: Development and Testing of a Quantitative Hierarchical Levels of Evidence Schema *M.N. Lassere, K.R. Johnson, M. Boers, et al* 607

Simulation Studies of Surrogate Endpoint Validation Using Single Trial and Multitrial Statistical Approaches *M. Lassere, K. Johnson, M. Hughes, et al.* 616

Synovial Macrophages as a Biomarker of Response to Therapeutic Intervention in RA: Standardization and Consistency Across Centers *B. Bresnihan, D.M. Gerlag, T. Rooney, et al* 620

Testing of the Preliminary OMERACT Validation Criteria for a Biomarker to Be Regarded as Reflecting Structural Damage Endpoints in RA Clinical Trials: The Example of CRP *S.O. Keeling, R. Landewé, D. van der Heijde, et al.* 623

Development of Draft Validation Criteria for a Soluble Biomarker to Be Regarded as a Valid Biomarker Reflecting Structural Damage Endpoints in RA and SpA Clinical Trials *W.P. Maksymowych, R. Landewé, M. Boers, et al.* . 634

Assessing Single Joints in Arthritis Clinical Trials *J.T. Giles, P. Mease, M. Boers, et al.* 641

Letters

Sarcoid-like Granulomatous Disease Following Etanercept Treatment for RA *A. Kudrin, E.R. Chilvers, A. Ginawi, et al.* 648

CRP in Primary Antiphospholipid Syndrome *P.R.J. Ames, C. Tommasino, V. Brancaccio, A. Ciampa* 650

Meetings in Rheumatology